Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Chk1 inhibition significantly potentiates activity of nucleoside analogs in TP53-mutated B-lymphoid cells

J. Zemanova, O. Hylse, J. Collakova, P. Vesely, A. Oltova, M. Borsky, K. Zaprazna, M. Kasparkova, P. Janovska, J. Verner, J. Kohoutek, M. Dzimkova, V. Bryja, Z. Jaskova, Y. Brychtova, K. Paruch, M. Trbusek,

. 2016 ; 7 (38) : 62091-62106.

Language English Country United States

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc18025325

Grant support
NV15-29793A MZ0 CEP Register
NV15-33999A MZ0 CEP Register

Treatment options for TP53-mutated lymphoid tumors are very limited. In experimental models, TP53-mutated lymphomas were sensitive to direct inhibition of checkpoint kinase 1 (Chk1), a pivotal regulator of replication. We initially tested the potential of the highly specific Chk1 inhibitor SCH900776 to synergize with nucleoside analogs (NAs) fludarabine, cytarabine and gemcitabine in cell lines derived from B-cell malignancies. In p53-proficient NALM-6 cells, SCH900776 added to NAs enhanced signaling towards Chk1 (pSer317/pSer345), effectively blocked Chk1 activation (Ser296 autophosphorylation), increased replication stress (p53 and γ-H2AX accumulation) and temporarily potentiated apoptosis. In p53-defective MEC-1 cell line representing adverse chronic lymphocytic leukemia (CLL), Chk1 inhibition together with NAs led to enhanced and sustained replication stress and significantly potentiated apoptosis. Altogether, among 17 tested cell lines SCH900776 sensitized four of them to all three NAs. Focusing further on MEC-1 and co-treatment of SCH900776 with fludarabine, we disclosed chromosome pulverization in cells undergoing aberrant mitoses. SCH900776 also increased the effect of fludarabine in a proportion of primary CLL samples treated with pro-proliferative stimuli, including those with TP53 disruption. Finally, we observed a fludarabine potentiation by SCH900776 in a T-cell leukemia 1 (TCL1)-driven mouse model of CLL. Collectively, we have substantiated the significant potential of Chk1 inhibition in B-lymphoid cells.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18025325
003      
CZ-PrNML
005      
20201116093824.0
007      
ta
008      
180709s2016 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.18632/oncotarget.11388 $2 doi
035    __
$a (PubMed)27556692
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Zemanova, Jana $u Department of Internal Medicine - Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
245    10
$a Chk1 inhibition significantly potentiates activity of nucleoside analogs in TP53-mutated B-lymphoid cells / $c J. Zemanova, O. Hylse, J. Collakova, P. Vesely, A. Oltova, M. Borsky, K. Zaprazna, M. Kasparkova, P. Janovska, J. Verner, J. Kohoutek, M. Dzimkova, V. Bryja, Z. Jaskova, Y. Brychtova, K. Paruch, M. Trbusek,
520    9_
$a Treatment options for TP53-mutated lymphoid tumors are very limited. In experimental models, TP53-mutated lymphomas were sensitive to direct inhibition of checkpoint kinase 1 (Chk1), a pivotal regulator of replication. We initially tested the potential of the highly specific Chk1 inhibitor SCH900776 to synergize with nucleoside analogs (NAs) fludarabine, cytarabine and gemcitabine in cell lines derived from B-cell malignancies. In p53-proficient NALM-6 cells, SCH900776 added to NAs enhanced signaling towards Chk1 (pSer317/pSer345), effectively blocked Chk1 activation (Ser296 autophosphorylation), increased replication stress (p53 and γ-H2AX accumulation) and temporarily potentiated apoptosis. In p53-defective MEC-1 cell line representing adverse chronic lymphocytic leukemia (CLL), Chk1 inhibition together with NAs led to enhanced and sustained replication stress and significantly potentiated apoptosis. Altogether, among 17 tested cell lines SCH900776 sensitized four of them to all three NAs. Focusing further on MEC-1 and co-treatment of SCH900776 with fludarabine, we disclosed chromosome pulverization in cells undergoing aberrant mitoses. SCH900776 also increased the effect of fludarabine in a proportion of primary CLL samples treated with pro-proliferative stimuli, including those with TP53 disruption. Finally, we observed a fludarabine potentiation by SCH900776 in a T-cell leukemia 1 (TCL1)-driven mouse model of CLL. Collectively, we have substantiated the significant potential of Chk1 inhibition in B-lymphoid cells.
650    _2
$a zvířata $7 D000818
650    _2
$a apoptóza $7 D017209
650    _2
$a B-lymfocyty $x cytologie $7 D001402
650    _2
$a buněčný cyklus $7 D002453
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a proliferace buněk $7 D049109
650    _2
$a viabilita buněk $7 D002470
650    _2
$a checkpoint kinasa 1 $x antagonisté a inhibitory $7 D000071877
650    _2
$a cytarabin $x aplikace a dávkování $7 D003561
650    _2
$a deoxycytidin $x aplikace a dávkování $x analogy a deriváty $7 D003841
650    _2
$a screeningové testy protinádorových léčiv $7 D004354
650    _2
$a lidé $7 D006801
650    _2
$a chronická lymfatická leukemie $x farmakoterapie $x genetika $x metabolismus $7 D015451
650    _2
$a myši $7 D051379
650    _2
$a myši transgenní $7 D008822
650    _2
$a mitóza $7 D008938
650    _2
$a mutace $7 D009154
650    _2
$a nukleosidy $x genetika $7 D009705
650    _2
$a pyrazoly $x farmakologie $7 D011720
650    _2
$a pyrimidiny $x farmakologie $7 D011743
650    _2
$a signální transdukce $7 D015398
650    _2
$a nádorový supresorový protein p53 $x genetika $7 D016159
650    _2
$a vidarabin $x aplikace a dávkování $x analogy a deriváty $7 D014740
655    _2
$a časopisecké články $7 D016428
700    1_
$a Hylse, Ondrej $u Center of Biomolecular and Cellular Engineering, International Clinical Research Center, St. Anne's University Hospital, Brno, Czech Republic. Department of Chemistry, CZ Openscreen, Faculty of Science, Masaryk University, Brno, Czech Republic.
700    1_
$a Collakova, Jana $u Institute of Physical Engineering, Faculty of Mechanical Engineering, Brno University of Technology, Brno, Czech Republic. CEITEC - Central European Institute of Technology, Brno University of Technology, Brno, Czech Republic.
700    1_
$a Vesely, Pavel $u CEITEC - Central European Institute of Technology, Brno University of Technology, Brno, Czech Republic.
700    1_
$a Oltova, Alexandra $u Department of Internal Medicine - Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Borsky, Marek $u Department of Internal Medicine - Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Zaprazna, Kristina $u CEITEC - Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
700    1_
$a Kasparkova, Marie $u Department of Internal Medicine - Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Janovska, Pavlina $u Institute of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic.
700    1_
$a Verner, Jan $u Department of Internal Medicine - Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Kohoutek, Jiri $u Department of Chemistry and Toxicology, Veterinary Research Institute, Brno, Czech Republic.
700    1_
$a Dzimkova, Marta $u Department of Chemistry and Toxicology, Veterinary Research Institute, Brno, Czech Republic.
700    1_
$a Bryja, Vitezslav $u Institute of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic. Department of Cytokinetics, Institute of Biophysics, Academy of Sciences of the Czech Republic, Brno, Czech Republic.
700    1_
$a Jaskova, Zuzana $u Department of Internal Medicine - Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Brychtova, Yvona $u Department of Internal Medicine - Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Paruch, Kamil $u Center of Biomolecular and Cellular Engineering, International Clinical Research Center, St. Anne's University Hospital, Brno, Czech Republic. Department of Chemistry, CZ Openscreen, Faculty of Science, Masaryk University, Brno, Czech Republic.
700    1_
$a Trbusek, Martin $u Department of Internal Medicine - Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
773    0_
$w MED00184852 $t Oncotarget $x 1949-2553 $g Roč. 7, č. 38 (2016), s. 62091-62106
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27556692 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180709 $b ABA008
991    __
$a 20201116093823 $b ABA008
999    __
$a ok $b bmc $g 1317456 $s 1022246
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 7 $c 38 $d 62091-62106 $i 1949-2553 $m Oncotarget $n Oncotarget $x MED00184852
GRA    __
$a NV15-29793A $p MZ0
GRA    __
$a NV15-33999A $p MZ0
LZP    __
$a Pubmed-20180709
Back

Find record

Citation metrics

Archiving options